Background-Several cell-based therapies for adjunctive treatment of acute myocardial infarction have been investigated in multiple clinical trials, but the benefits still remain controversial. This meta-analysis aims to evaluate the efficacy of bone marrow-derived mononuclear cell (BMMNC) therapy in patients with acute myocardial infarction, but also explores the effect of newer generations of stem cells. Methods and Results-A random-effects meta-analysis was performed on randomized controlled trials investigating the effects of stem cell therapy in patients with acute myocardial infarction that were published between January 2002 and September 2013. The defined end points were left ventricular (LV) ejection fraction, LV end-systolic and end-diastolic volumes, infarct size, and major adverse cardiac and cerebrovascular event rates. Also, several subgroup analyses were performed on BMMNC trials. Overall, combining the results of 22 randomized controlled trials (RCTs), LV ejection fraction increased by +2.10% (95% confidence interval [CI], 0.68-3.52; P=0.004) in the BMMNC group as compared with controls, evoked by a preservation of LV end-systolic volume (−4.05 mL; 95% CI, −6.91 to −1.18; P=0.006) and a reduction in infarct size (−2.69%; 95% CI, −4.83 to −0.56; P=0.01). However, there is no effect on cardiac function, volumes, or infarct size, when only RCTs (n=9) that used MRI-derived end points were analyzed. Moreover, no beneficial effect could be detected on major adverse cardiac and cerebrovascular event rates after BMMNC infusion after a median follow-up duration of 6 months. 
D
espite advancements in treatment options, ischemic heart failure (IHF) remains the leading cause of morbidity and mortality in the Western world. 1 Therefore, the search for new therapeutic strategies to prevent adverse ventricular remodeling after acute myocardial infarction (AMI) and subsequent development of IHF is ongoing. More than a decade after a patient with an AMI was first treated with intracoronary infusion of unfractioned bone marrow-derived mononuclear cells (BMMNCs), 2 numerous clinical studies have investigated cell-based therapy as an adjuvant treatment in patients with AMI. These studies have repeatedly shown that stem cell therapy is safe and feasible. However, although initial results were promising with significant improvement in left ventricular (LV) function and volumes, [3] [4] [5] other studies showed ambiguous or even negative results. [6] [7] [8] [9] This controversy resulted in a continued search for new cell types and methods to improve outcomes, but still many questions remain.
Thus far, it has been difficult to make solid statements on efficacy and long-term effects on clinical outcomes of cellular therapy because of the limited number of treated patients and the relatively short follow-up period. However, recently, some larger studies reported their primary results, whereas other studies presented long-term follow-up data. 5, [10] [11] [12] Several meta-analysis regarding BMMNCs for the treatment of AMI and IHF have been published to date. [13] [14] [15] These analyses showed an improvement of only 2% to 3% on LV ejection fraction (LVEF) and a significant reduction of major adverse cardiac and cerebrovascular events (MACCE; eg, all-cause mortality; odds ratio [OR] , 0.39; 95% confidence interval [CI] , 0.27-0.55).
14 However, these publications only evaluated the use of autologous BMMNC on cardiac repair, whereas several other cell types have now been investigated. Moreover, in the most cited meta-analysis of Jeevanantham et al, 14 data of AMI and IHF patients were pooled for the evaluation of clinical outcome parameters and subgroup analyses, which might have clouded the outcome in AMI patients.
The current meta-analysis focuses solely on AMI patients, who have been treated with an infusion of BMMNC, but also autologous or allogeneic mesenchymal stem cells (MSCs), adipose tissue-derived regenerative cells, or cardiosphere-derived cells (CDCs) . It thereby provides a side-by-side comparison of BMMNCs and other cell populations in patients with AMI.
Methods
This meta-analysis was executed according to the Quorum statements. 16 Briefly, a random-effect meta-analysis was performed that included all RCTs regarding stem cell therapy for the treatment of AMI, published on Medline (PubMed) between July 2002 and September 2013. BMMNCs were the main focus in this study, because the majority of studies to date assessed this specific cell type. Moreover, the effects of BMMNC therapy were compared with newer generations of stem cells, including MSCs, bone marrow progenitors (CD133 + /CD34 + cells), adipose tissue-derived regenerative cells, and CDCs. The following search strategy was applied: stem cells, progenitor cells, mononuclear cells, adipose tissue-derived regenerative cells, MSCs, cardiac-derived stem cells, bone marrow, vascular stromal fraction, adipose stem cells, mesenchymal-like stem cells, coronary artery disease, myocardial infarction, cardiac repair, and myocardial regeneration. Only articles published in English were included (Table I in the Data Supplement). Studies were included that met the following criteria: (1) RCTs with an appropriate control group who received standard therapy, (2) conducted in patients with an AMI that occurred <3 months before, (3) using stem cells that were administered by intracoronary or intravenous injection, (4) total number of patients enrolled should exceed 10, (5) stem cells were derived from adipose tissue, bone marrow, or heart, and (6) given in an allogeneic or autologous setting.
Data abstraction and analysis was performed by 3 different researchers (R.d.J., J.H., S.S.) and reported on standardized forms. LVEF, LV end-systolic volume (LVESV), LV end-diastolic volume (LVEDV), and infarct size were assessed as outcome measures as well as clinical outcome. Additional subgroup analyses were performed within the RCTs that investigated BMMNC therapy, in an attempt to gain more insight into possible discriminating parameters or conditions that might improve outcome in future trials.
Subgroup analyses conducted included: (1) follow-up duration of 6 months, 6 to 18 months, and 18 to 60 months; (2) different imaging modalities that were used to assess LVEF, LV volumes, and infarct size; (3) LVEF at baseline (<40%, <45%, <50%, >50%); (4) amount of infused cells (<50 million, <100 million, >100 million), (4) timing of delivery (<2 days, 2-7 days [7 days was the median in this analysis], >8 days after MI); (5) delivery method (intracoronary stop-flow technique, continuous intracoronary infusion); (6) location of AMI (anterior wall versus all other AMI locations); (7) cell preparation method and use of heparin in the final cell suspension; and (8) Lymphoprep versus Ficoll-based isolation.
Data Analysis
LV function was the primary end point of our analysis. In particular, we studied the difference in mean LVEF change (from baseline to follow-up) between patients receiving stem cells and control treatment. We applied inverse-variance weighting to combine the results from independent studies. Most studies reported mean LVEF±1 SD at baseline and follow-up. The mean LVEF change was then determined as LVEF follow-up −LVEF baseline , whereas SD change was estimated according to the method described by Hristov et al. 17 For studies that report SEM, SDs were determined as SEM*√(sample size). In case interquartile ranges are reported, SDs are estimated as (range/4). We applied a random-effects model to obtain an overall estimate of the treatment effect, which we report as point estimate and 95% CI. Heterogeneity was analyzed with the I 2 statistic and was defined as low (25%-50%), intermediate (50%-75%), or high (>75%).
We applied a similar methodology to study several secondary end points, including (mean changes in) LVESV and LVEDV, infarct size as measured by cardiac MRI, and perfusion defect as measured by single photon emission computerized tomography. We applied the Mantel-Haenszel OR to obtain an overall estimate of the OR for MACCE, again assuming random effects.
All analyses were performed using Review Manager 5.2 analysis software (Rev Man, version 5.2; The Nordic Cochrane Center, The Cochrane Collaboration, 2012). We considered P values <0.05 (2-sided) as statistically significant. Funnel plots were constructed to explore publication bias.
A detailed description of methods can be found in the Data Supplement.
Results

Search Results
The final search on September 1, 2013, resulted in a total of 386 articles. A majority of articles were excluded due to other types of study subjects (chronic heart failure or granulocytecolony stimulating factor treatment) or duplicate reports or reviews, resulting in a total of 47 studies. When cohort studies were omitted, 42 articles remained. [3] [4] [5] [6] [7] 10, 11, Finally, a total of 30 RCTs were used in this meta-analysis, comprising a total of 2037 patients, 1218 of whom were treated with cells ( Figure [ 
WHAT IS KNOWN
• In previous meta-analyses, intracoronary infusion of bone marrow-derived mononuclear cells (BMMNC) resulted in an overall mild improvement of global left ventricular ejection fraction after an acute myocardial infarction (AMI).
• In these meta-analyses, pooling of AMI and heart failure patients suggested a reduction of major adverse cardiac and cerebrovascular events (MACCE) in patients after treatment with BMMNC.
• New candidate cells for heart repair, including cardiospheres and mesenchymal stem cells, are being evaluated in clinical trials.
WHAT THE STUDy ADDS
• When more recent, large randomized controlled trials are included in the meta-analysis, the overall benefit on clinical outcome (MACCE) and cardiac function is lost.
• When restricted to patients with AMI, the meta-analysis showed that intracoronary infusion of BMMNC did not result in a reduction of all-cause mortality, cardiac mortality, or recurrent AMI hospitalizations for heart failure or stroke, despite >1500 patients analyzed.
• This is the first meta-analysis that includes data from studies using novel stem cell therapy approaches for cardiac repair.
bone marrow progenitors, and 1 trial investigated the effects of CDCs.
Study Quality
The quality of RCTs was assessed by the Jüni criteria (Table  II in the Data Supplement) . 53 In 60% of RCTs, patients and investigators were not blinded to cell intervention. Control patients did not undergo a sham biopsy and infusion of cells in most of these studies. Patient follow-up was completed in all studies.
Study Characteristics
The average of participating patients per study was 68±51, whereas the median was 45 patients (range, 14-200). Most studies used a 1:1 randomization scheme. The median follow-up duration in all studies was 6 months (range, 3-60 months). The median amount of infused viable cells was 100 million (range, 5×10 6 to 60×10 9 ), and the cells were infused after a median duration of 7 days (range, <24 hours to 3 months). MRI was the imaging modality of choice for follow-up of LV function in 40% of RCTs (Table III in 
BMMNC: Cardiac Parameters
Overall, BMMNC infusion increased LVEF by +2.10% (95% CI, 0.68-3.52; P=0.004; Figure 1A 
BMMNC: Subgroup Analyses
Effects of BMMNC Transplantation Over Time Subgroup analysis revealed that at 6 months of follow-up (n=21 RCTs), LVEF increased by +2.08% (95% CI, 0.55-3.60; P=0.008; Table 1 ). At 12 months (n=8), this beneficial effect was sustained and increased to a more pronounced effect of +3.04% (95% CI, 1.27-4.81; P=0.0008) when compared with control. At 36 to 60 months of follow-up (n=3), this treatment effect disappeared to +1.19% (95% CI, −2.74 to 5.12; P=0.55; Table 1 ). This increase in LVEF up to 18 months of follow-up was mainly because of a preservation of LVESV in the BMMNC group (as opposed to the control group). In the treatment group, LVESV progressively decreased by −4.84 mL (95% CI, −7.69 to −2.00; P=0.0008) at 6 months of follow-up and −3.56 mL at 18 months of follow-up (95% CI, −6.87 to −0.25; P=0.03). Infarct size was significantly reduced at 6 (−2.69%; 95% CI, −4.83 to −0.56; P=0.01) and 18 months of follow-up (−3.71%; 95% CI, −6.99 to −0.43; P=0.03). This significant effect on infarct size diminished at long-term follow-up (>18 months; −0.82%; 95% CI, −3.78 to 2.15; P=0.59).
Imaging Modality
Interestingly, when subgroup analysis was performed based on MRI (n=9), which is currently considered the gold standard to assess cardiac function and volumes, the significant effect of BMMNC therapy on LVEF diminished (0.13%; 95% CI, −2.67 to 2.93; P=0.93). Also, the beneficial effect on LV volumes and infarct size disappeared (Table 2 ). This finding could indicate that BMMNC therapy is not beneficial in patients with AMI. Figure 2 ). Remarkably, we found a significant increase of LVEDV in CD133/CD34 + patient group by +14.06 mL (95% CI, 9.63-18.48) as opposed to a decrease by −2.80 mL in BMMNC patient group (−6.03 to 0.44; P for subgroup differences <0.00001). Table 3 summarizes the functional parameters of other cell types as opposed to BMMNC and other subgroup analysis. CDCs were omitted from further comparison, because only 1 trial investigated this new cell type.
BMMNC Versus Other Cell Types
Infarct Location and LV Function at Baseline
Patients with an anterior wall AMI due to the occlusion of left descending artery did not benefit more from stem cell therapy compared with patients with an AMI located elsewhere (Table 3 ). According to our data, patients with a lower LVEF (<40% or <45%) at baseline did not benefit more from cell therapy compared with patients with a higher LVEF. Only the beneficial effect of BMMNC therapy on infarct size was significantly greater in patients with a LVEF <45% (−2.39%; 95% CI, −2.75 to −2.02), as opposed to almost no reduction (−0.50%; 95% CI, −2.36 to 0.27) in patients with a LVEF >45% (P for subgroup differences=0.05).
Parameters Related to Cell Infusion
The median cell number infused was 100 million. Intriguingly, total cell number did not predict the outcome. More specifically, patients treated with an infusion of <100 million cells did not benefit more or less from cell infusion compared with patients with higher cell doses. BMMNC transplantation before day 8 resulted in improved LVEF (+3.10%; 95% CI, 1.49 -4.70; P=0.009) as opposed to late infusion (−0.37%; 95% CI, −2.40 to 1.66).
Intracoronary Delivery Technique
We found that performing a subgroup analysis on intracoronary delivery technique was not feasible, because in all studies, except 2, the stop-flow technique was adopted.
Cell Preparation
Subgroup analysis based on the methods of BMMNC isolation revealed that all trials, except 2, 6,33 used Ficoll-based isolation; therefore, subgroup analysis was not useful. The final suspension of cell preparation in heparin-containing saline or in nonheparinized solutions did not have a significant effect on treatment outcome.
Safety of Intracoronary Cell Infusion and MACCE Rates
In a majority of trials, intracoronary infusion of stem cells did not result in procedure-related adverse events, or adverse events were not reported in the article. Only 1 study described a case of thrombosis in infarct-related artery after AMI and 3 cases of intima dissection after balloon inflation during transplantation. 26 The median follow-up duration for MACCE rates was 6 months. Intracoronary infusion of BMMNC did not result in a reduction of any MACCE. More specifically, and in contrast to previous reported meta-analysis, no differences on all-cause mortality, cardiac mortality, hospitalizations for heart failure, restenosis rate, thrombosis, target vessel revascularization, stroke, recurrent AMI, and implantable cardioverter defibrillator implantations were detected between BMMNC patients and controls (Table 4) . Bone marrow progenitor cell infusion resulted in a reduction in rehospitalizations for heart failure (OR, 0.14; 95% CI, 0.04-0.52; P=0.003), and MSC transplantation resulted in a reduction in ventricular fibrillation/ventricular tachycardia (OR, 0.08; 95% CI, 0.01-0.79; P=0.03) and implantable cardioverter defibrillator implantations (OR, 0.08; 95% CI, 0.01-0.79; P=0.03).
Publication Bias
A funnel plot for LVEF showed that studies were equally distributed around the overall estimate, suggesting that there was no sign for publication bias (Figure [B] in the Data Supplement). The beneficial effect of BMMNC therapy on left ventricular ejection fraction (LVEF) was maintained during 18-y follow-up. This effect on LVEF was mainly because of a preservation of LV end-systolic volume (LVESV). The effects diminished after an 18-mo follow-up. CI indicates confidence interval; IS, infarct size; and LVEDV, LV end-diastolic volume.
Discussion
In this meta-analysis, which comprises a total of 2037 patients with AMI, cell therapy proved to be safe. BMMNC therapy modestly improved LVEF at short-and long-term follow-up when all imaging modalities are combined for analysis. The modest improvement in LVEF was mainly because of a sustained LVESV, accompanied by a reduction in infarct size. Interestingly, when only studies are analyzed that used cardiac MRI for measuring volumes and LVEF, this beneficial effect of BMMNC therapy on cardiac function disappeared. Furthermore, the occurrence MACCE is not reduced in patients treated with BMMNC when compared with controls.
MACCE Rates
One of the most salient findings of the current meta-analysis is the fact that, despite >1500 patients analyzed to date, BMMNC therapy did not affect clinical outcome measures in AMI patients. Our findings seem contradictory to findings in recent meta-analyses by Jeevanantham et al 14 who described a reduction in all-cause mortality, cardiac mortality, recurrent AMI, hospitalizations for heart failure, and in-stent thrombosis after BMMNC transplantation. However, in this meta-analysis, both AMI and IHF patients were combined for the assessment of clinical outcome. We hypothesize that patients with IHF may benefit more from cell therapy, which was corroborated in a recent meta-analysis that solely focused on patients with IHF. 15 The current analysis includes, for the first time to our knowledge, recent negative publications such as the Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI) trial and A Phase-II, Randomized, Double-Blinded, Placebo-Controlled, Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells 2 to 3 Weeks After Acute Myocardial Infarction (LateTIME) trial, which have modified the results. It should be noted that the median follow-up duration for the assessment of MACCE rates is only 6 months, which might be too short to draw conclusions regarding clinical outcome. We performed a power analysis to calculate the number of patients needed to discriminate a possible beneficial effect of cell therapy in patients with AMI. Based on our data, we found that a study of 2994 patients would be needed to demonstrate a possible effect on MACCE when the incidence of an event was 20% (Table  IV in the Data Supplement), whereas >30 000 patients would be needed to demonstrate an effect if the incidence of an event was 2%. In our meta-analysis, the incidence of all-cause mortality was only 2% at a median follow-up duration of 6 months. The forthcoming phase III Bone Acute Myocardial Infarction (BAMI) trial (NCT01569178) is designed to shed more light on the value of BMMNC therapy in improving clinical outcome. It is designed to compare BMMNC transplantation in AMI patients with baseline LVEF <45% to a control group that receives optimal medical care. The primary end point in this study is time from randomization to all-cause mortality during a 3-year follow-up. A secondary outcome measure is the occurrence of other MACCE from randomization up until 3 years of follow-up. LV function, volumes, and infarct size are not outcome measures in this trial.
Our power analysis is based on multiple small studies. All these individual studies were primarily designed as safety and feasibility studies and, thus, inadequately powered to detect an effect on clinical end points, whereas the BAMI trial was powered based on long-term follow-up data of the landmark Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. 24 More importantly, the median follow-up in our meta-analysis is only 6 months, which is rather short to notice effects on clinical outcome measures in this era of aggressive primary interventions and pharmacotherapy. However, it remains questionable whether the BAMI trial is sufficiently powered to establish definitive answers. Nonetheless, we think that the BAMI trial will shed more light on several questions concerning BMMNC therapy as adjunctive treatment for AMI patients, and the final results are much anticipated. Table V in the Data Supplement summarizes all upcoming clinical trials on stem cell therapy for AMI. Currently, newer generations of more potent stem cells are emerging in the field of cardiology. Our meta-analysis revealed a reduction in rehospitalizations for heart failure or reduction in ventricular arrhythmias and implantable cardioverter defibrillator implantations in patients treated with these newer-generation cells. However, the number of clinical trials to date is limited, which is why no statement could be made about the superiority of these cells yet.
Cell Therapy-Related Parameters Possibly Influencing Efficacy Outcomes
Timing of Cell Delivery
The optimal timing of cell therapy with respect to AMI remains unclear to date. Thus far, it was thought that cell therapy should be initiated 3 to 10 days after the AMI, based on the findings in phase I studies, logistical issues, and the assumption that in the first 72 hours the infarct territory encompasses a too hostile environment for the infused cells. Others argued that stem cells should be infused as soon as possible to prevent cardiomyocyte loss by secreted anti-inflammatory, prosurvival, and antiapoptotic paracrine factors. 54 This hypothesis was recently supported by preclinical and clinical evidence. 50, 55 Nevertheless, to date, almost all (>90%) other clinical studies infused stem cells >72 hours after the AMI. In this meta-analysis, we found that timing of BMMNC infusion later than 8 days did not seem to be effective. This was confirmed by recent trials aimed to address the question of cell therapy timing. [10] [11] [12] 39 The TIME and LateTIME and SWISS-AMI failed to show any beneficial effect of late infusion as opposed to early infusion. MACCE rates were not reduced in bone marrow-derived mononuclear cell (BMMNC)-treated patients. In patients treated with BM progenitor cells, the rehospitalizations for heart failure were lower as opposed to the control group. Intracoronary infusion of mesenchymal stem cells (MSCs) resulted in lower number of VT/VF and implantable cardioverter defibrillator (ICD) implantations. It has to be kept in mind that the trials to date were not sufficiently powered to detect differences in clinical outcome. CI indicates confidence interval; CVA, cerebrovascular accident; MI, myocardial infarction; TVR, target vessel revascularization; VF, ventricular fibrillation; and VT, ventricular tachycardia. 
Cell Type
It is currently hypothesized that culture-expanded subpopulations of BMMNCs or other specialized cell types might exhibit more cardioprotective effects compared with BMMNCs. 56 Indeed, a recent meta-analysis that compared all preclinical, large animal studies performed to date concluded that MSCs seem to have more pronounced beneficial effects on LV function compared with BMMNCs, 57 whereas newer-generation cells might be even more effective. In this meta-analysis, we found a trend toward an improvement in cardiac function in patients treated with MSCs. However, only limited numbers of patients are treated with this stem cell type to date, rendering a high heterogeneity between trials. A power calculation revealed that a study of 106 patients per group is needed to detect a possible significant benefit of MSCs over BMCs. Forthcoming AMICI (NCT01781390) and ADVANCE (NCT01216995) are both phase IIa/IIb trials designed to investigate the effects of mesenchymal-like cells on cardiac repair in >200 patients. Therefore, they might provide evidence of superiority of MSCs. It should be noted, however, that both studies do not perform head-to-head comparisons of MSCs and BMMNCs.
Cell Preparation and Infusion
Recently, it was suggested that the use of heparin in the final stem cell suspension might interfere with the SDF-1/CXCR4 axis, thereby resulting in decreased homing of BMCs. 58 However, we found that the use of heparin during cell preparation did not seem to influence therapy outcome. Contrarily, there seems to be a trend toward a beneficial effect on LVEF in heparin-treated cells, which was also found by Jeevanantham et al. 14 We also confirm their finding that the BMMNC isolation protocol did not seem to influence therapy outcome. Noteworthy, only 2 trials prepared BMMNCs via a different method than Ficoll isolation.
Cardiac MRI and Study Design as Effect Modifier?
Although the effect we found on LVEF in this meta-analysis is limited, it can have significant clinical implications. For instance, in studies that assessed the effect of primary PCI after AMI, a similar modest 4% improvement in LVEF was found that eventually amounted to pronounced effects on mortality. 59, 60 However, despite early enthusiasm and several previous positive meta-analyses on cellular therapy, 9, 14 it seems that some consideration is justified.
First, and most importantly, in most of the earlier cell therapy trials that drove initial enthusiasm, LVEF and volumes were assessed by LV angiography or echocardiography, whereas cardiac MRI is currently considered the gold standard. 61 Most recent stem cell trials, however, used MRI-based analysis for primary end point measures of efficacy and volumes, and 40% of all trials in the current meta-analysis used MRI. 6, 7, 11, 12, 23, 31, 38, 49 Intriguingly, when our data are corrected for the use of MRI as imaging tool, the positive effect of cell therapy on LVEF, volumes, and infarct size diminishes. This finding corroborates the exploratory findings of Traverse et al 62 and puts the initial enthusiasm concerning BMMNC-based therapies for AMI patients in a different perspective.
Noteworthy, ≈50% of RCTs in this meta-analysis was not executed according to the Jüni criteria (Table II in the Data Supplement), because they do not perform a bone marrow biopsy and sham injection procedure in placebo patients. However, in most studies, an unbiased outcome was ascertained by blinded core laboratory analysis.
Considerations
We think that the current meta-analysis shows strong indications that BMMNC therapy in patients with AMI is not effective in improving clinical outcome. Although the number of patients treated with next-generation cell therapies is still too low, and studies performed to date were primarily designed to prove safety and feasibility, these new therapies might prove to be more effective. It is thought that mesenchymal cell populations or cardiac-derived stem cells exhibit more cardioprotective and regenerative potential. Importantly, preclinical and preliminary clinical evidence shows promising benefits of these cell types. [49] [50] [51] 55, 57 Moreover, MSCs are immune-privileged cells and can be administered in an allogeneic setting. This renders the possibility of an allogeneic off-the-shelf cell product, which is readily available directly after primary PCI. This has several logistical advantages, but might also enhance outcome, because it was shown that stem cells derived from young and healthy donors perform better and have more regenerative potential compared with autologous stem cells from typically elderly cardiovascular patients. 63 
Novelty/Significance
The current meta-analysis, consisting of 30 published RCTs and comprising a total of 2037 patients, is to date the largest meta-analysis on stem cell therapy for the treatment of patients with AMI. It includes recently published, relatively large RCTs that used MRI-derived parameters as surrogate end point and were not included in any meta-analysis yet. 6, 10 Also, for the first time to our knowledge, studies that investigated other cell types than BMMNCs were included in a subgroup analysis. 50, 51 In contrast to a recently published meta-analysis that combined AMI and heart failure patients in most of its subgroup analyses, the current article focuses solely on AMI patients, rendering different and sometimes opposing conclusions.
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Conclusions
Intracoronary infusion of BMMNCs improves LVEF by +2.10%, mostly by reduction of LVESV and infarct size. However, there is no beneficial effect on global LVEF when restricted to cardiac MRI analysis. The improvement in LVEF did not lead to a reduction in clinical outcome. Newer generations of stem cells with a better profile for cardiac repair are emerging, but their future role still needs to be defined in phase II and III studies.
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